Author

S. Betzi

Primary ORCID profile (0000-0001-5935-5058 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

S. BetziiD1 paper · Centre National de la Recherche Scientifique

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Approach:statistical model· 1

Frequent Co-Authors

L. Hoffer· 3 shared X. Morelli· 3 shared C. Derviaux· 2 shared E. Pasquier· 2 shared K. Carrasco· 2 shared P. Roche· 2 shared Y. Collette· 2 shared A. Restouin· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

L. Hoffer

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CRCM5484: A BET- BDII Selective Compound With Differential Anti-Leukemic Drug Modulation

K. Carrasco, C. Montersino, C. Derviaux, M. Saez-Ayala, L. Hoffer, A. Restouin, R. Castellano, J. Casassa, P. Roche, E. Pasquier, S. Combes, X. Morelli, Y. Collette, S. Betzi

The paper identifies CRCM5484, a BDII-selective BET inhibitor, and shows its differential modulation of anti-leukemic drug activity in combination with other compounds.

bioRxiv · Dec 13, 2021Cancer Biology

Discovery of small molecule inhibitors of the PTK7/β-catenin interaction targeting the Wnt signaling pathway in colorectal cancer

L. Ganier, S. Betzi, C. Derviaux, P. Roche, C. Muller, L. Hoffer, X. Morelli, J.-P. Borg

This study identifies small molecule inhibitors of the PTK7/β-catenin interaction in colorectal cancer, showing anti-proliferative effects in cells with Wnt pathway mutations.

bioRxiv · Oct 15, 2021 · PreprintPharmacology & Toxicology

In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor

J. Ariey-Bonnet, K. Carrasco, M. Le Grand, L. Hoffer, S. Betzi, M. Feracci, P. Tsvetkov, F. Devred, Y. Collette, X. Morelli, P. Ballester, E. Pasquier

This paper identifies mebendazole as a potent MAPK14 inhibitor through in silico target prediction and experimental validation, revealing its potential for repurposing in brain tumor treatment.

bioRxiv · May 18, 2020Pharmacology & Toxicology